MRTX Mirati Therapeutics Inc.

102.62
-2.18  -2%
Previous Close 104.8
Open 105.4
Price To Book 9.31
Market Cap 4,046,963,573
Shares 39,436,402
Volume 538,911
Short Ratio
Av. Daily Volume 729,640
Stock charts supplied by TradingView

NewsSee all news

  1. Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting

    SAN DIEGO, Nov. 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of

  2. Mirati Therapeutics Reports Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2019. Recent

  3. Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting

    SAN DIEGO, Oct. 23, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, announced that the Company will have two presentations at the Society for Immunotherapy of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 update at SITC November 2018 - 5/29 partial responses.
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 Mechanism of Action data presented at SITC 2019.
Sitravatinib and Nivolumab
Renal cell carcinoma (RCC)
Phase 3 interim analysis 4Q 2020, final data 4Q 2021.
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
Phase 1b initial data due 4Q 2019.
Sitravatinib and tislelizumab
Solid tumors
Phase 1/2 updated data due 2020.
MRTX849
Solid tumors
Phase 2 initial data presented at SITC November 9, 2019 noted 6/22 ORR, 21/22 SD.
Sitravatinib
Urothelial Carcinoma (Bladder)

Latest News

  1. Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting

    SAN DIEGO, Nov. 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of

  2. Mirati Therapeutics Reports Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2019. Recent

  3. Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting

    SAN DIEGO, Oct. 23, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, announced that the Company will have two presentations at the Society for Immunotherapy of